10-K · March 12, 2026
Korro Bio, Inc.'s 2025 10-K report highlights significant operational changes as the company navigates through its clinical development phase while facing significant losses. The launch of its KRRO-121 therapy targeting…
Earnings analysis · 10-Q
KRRO earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
For Q1 2026, Korro Bio, Inc. reported a significant decline in collaboration revenue, falling to $0 from $2.6 million in Q1 2025, aligning with a strategic pause on collaboration with Novo Nordisk. Despite a reduction…
Read full summary
For Q1 2026, Korro Bio, Inc. reported a significant decline in collaboration revenue, falling to $0 from $2.6 million in Q1 2025, aligning with a strategic pause on collaboration with Novo Nordisk. Despite a reduction in operating expenses, the company recorded a net loss of $19.6 million, an improvement from the prior year's $23.4 million. The firm maintains a substantial cash position of $157.1 million, bolstered by a recent successful PIPE, allowing anticipated operations to extend into the second half of 2028.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-19.625
What stood out
-
Net Loss Improved
Net loss for Q1 2026 was $19.6 million, improved from $23.4 million in Q1 2025.
-
Cash and Security Position Strong
As of March 31, 2026, the company reported cash, cash equivalents, and marketable securities totaling $157.1 million.
-
Decrease in Operating Expenses
Total operating expenses decreased to $20.436 million from $27.570 million in Q1 2025.
-
Successful Capital Raising
Closed a PIPE in March 2026, raising approximately $85.0 million.
-
Collaboration Revenue Halted
Collaboration revenue dropped to $0 from $2.6 million due to a pause in the Novo Nordisk agreement.
-
Improved Loss from Operations
Loss from operations narrowed to $20.4 million, down from $25.0 million in Q1 2025.
What to watch
-
Extend of Net Operating Loss
Accumulated deficit reached $403.5 million as of March 31, 2026, raising liquidity concerns.
-
Ongoing Dependence on External Financing
The company anticipates the need for further capital as it does not expect revenue from product sales for several years.
-
Impact of Regulatory Changes
Future regulatory changes, especially regarding clinical and manufacturing processes, could complicate operations.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-Q · November 12, 2025
Korro Bio, Inc. reported a mixed Q3 2025, with actual revenue of $1.09 million surpassing estimates by 28.7%, although operating losses reduced only slightly compared to the prior period. The company is grappling with…
10-Q · August 12, 2025
Korro Bio, Inc. reported disappointing financial results for Q2 2025, with a revenue of $1.46 million compared to the consensus estimate of $406.9 million. Operating losses increased, with a reported EPS of -2.74. The…
10-Q · May 7, 2025
Korro Bio, Inc. reported a net revenue of $2.6 million in Q1 2025, up from $0 in Q1 2024, marking a significant improvement due mostly to its collaboration with Novo Nordisk. However, the company continues to incur…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.